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Patients with Advanced Lung Cancer: Is there Scope to Discontinue Inappropriate Medication? 
Abstract 
Background 
Polypharmacy – taking five or medications per day – is common in lung cancer patients.  This patient 
group is prescribed medication to control acute symptoms associated with cancer and also to 
prevent or treat other long-term conditions. These medications increase the pill burden for the 
patient and also the probability of developing a drug-related toxicity.   
Objective 
To assess the prevalence of inappropriate medication in patients taking erlotinib for the treatment 
of advanced non-small cell lung cancer.  
Method 
This was a multicentre study across three sites in the North of England.   Medication histories for 
patients receiving erlotinib were retrospectively extracted from medical notes and assessed by the 
clinical team (a consultant pharmacist, nurse specialist and clinical oncologist) to determine if the 
medication was appropriate or inappropriate.  The clinical team considered the following factors 
when deciding if the medication was appropriate or inappropriate: remaining life expectancy of the 
patient, time until benefit of the treatment, goals of care and treatment targets. 
Results  
Among the 20 patients assessed, 19 (95 per cent) according to the clinical team were taking 
medications that were inappropriate.  The mean number of medications the patients were taking 
was 8 (range 1 – 16) and the most common class of medication used were drugs affecting the 
Central Nervous System.  In addition, there were 11 patients (55 per cent) who were taking erlotinib 
in combination with a proton pump inhibitor (PPI) – a clinically significant drug interaction that 
impairs the absorption of erlotinib. 
Conclusions 
Patients taking erlotinib for the treatment of advanced non-small cell lung cancer take many 
inappropriate medications for the treatment or prevention of long-term conditions.  These patients 
should have their medications reviewed in the context of their original therapeutic goals. 
Keywords: non-small cell lung cancer, erlotinib, limited life expectance, inappropriate medication 
Impacts on Practice  
o Clear guidelines are needed on discontinuing inappropriate medication in patients with 
advanced lung cancer; 
o Wider information relating to patient medication history should be made available at the 
time of dispensing chemotherapy to facilitate a medication review; and, 
o Oncology units should have a clear policy for pharmacy to actively screen the medication 
history of all patients with advanced non-small cell lung cancer to establish if they are taking 
any interacting medicines prior to initiating erlotinib.   
Introduction  
Polypharmacy is associated with an increased risk of developing a drug-related toxicity due to the 
potential of drug-drug and drug-disease interactions.1,2 In cancer patients with limited life 
expectancy (LLE) – typically surviving for less than 1 year – polypharmacy is very common; 
medication is not only prescribed to control acute symptoms associated with cancer but is also used 
to prevent or treat other long-term conditions.3  These patient groups also have unique and dynamic 
pharmacokinetic and pharmacodynamics parameters (e.g. variation in volume of distribution or 
altered drug excretion due to declining renal and / or hepatic function), which further increases the 
probability of developing a drug-related toxicity.4,5   
In recent years, the problem of cancer patients with LLE developing a drug-related toxicity has been 
heightened by the introduction of targeted therapies – agents that block the growth and spread of 
cancer by interfering with specific cellular signals involved in tumor growth and progression.  Indeed, 
while targeted therapies have significantly improved positive outcomes for patients, they have also 
increased the risk of developing a drug-related toxicity.  For example, erlotinib – a tyrosine kinase 
inhibitor used for the treatment of advanced non-small cell lung cancer (NSCLC) – is metabolized, in 
part, by CYP1A1, CYP3A4 and CYP2D6, which significantly increases the risk of developing drug-drug 
interactions when using medicines that either inhibit or induce these isoenzymes – especially in 
patients with LLE.6 
In view of the potential for polypharmacy to cause harm in cancer patients with LLE, it is therefore 
essential to review and optimise medication to align with therapeutic goals and life expectancy.  This 
process may include discontinuing non-essential or inappropriate medication to reduce 
polypharmacy and, ultimately, the risk of developing a drug-related toxicity.  To date, there is limited 
research that reports whether inappropriate medication is being discontinued in cancer patients 
with LLE taking a targeted therapy. 
Aim of the Study 
The objective of the study was to assess the prevalence of inappropriate medication in cancer 
patients taking erlotinib for the treatment of advanced non-small cell lung cancer.  
Methods 
This was a multicentre retrospective study across three oncology units in the North of England.  All 
patients who had received erlotinib between April 2010 and April 2011 for the treatment of locally 
advanced or metastatic NSCLC after failure of previous chemotherapy were included in the study. 
Patients were excluded if the erlotinib was being used for another indication (e.g. for the treatment 
of metastatic pancreatic cancer).   
Medication histories for patients who had received erlotinib in the study period were retrospectively 
extracted from medical notes and sorted according to categories in the British National Formulary 
(BNF). When there was an ambiguity around the indication of the prescribed medication (e.g. for a 
medicine with several indications), the patient’s GP was contacted by telephone to establish the 
original prescribing indication of the medicine.  Once all of the medication was categorised, it was 
assessed by a consensus panel (a consultant pharmacist, nurse specialist and clinical oncologist) to 
determine if it was appropriate or inappropriate.  The clinical team used a framework described by 
Holmes and colleagues7 when deciding if the medication was appropriate or inappropriate; the 
following factors where considered: remaining life expectancy of the patient, time until benefit of 
the treatment, goals of care and treatment targets. 
The study was certified for ethical approval in accordance with the University of Sunderland ethics 
committee by the senior researcher (AT). 
Results  
Twenty patients were included in the study; the mean number of medications taken was 8 (range 1 – 
16) and the most common class of medication used were drugs affecting the Central Nervous System 
(Table 1).  The distribution of medication among patients were as follows: 
 7 patients (35 per cent) were taking medications which affected the cardiovascular system, e.g. 
beta blocking drugs, lipid-lowering drugs; 
 13 patients (65 per cent) were taking drugs which affected the gastrointestinal system, e.g. anti-
secretory drugs, mucosal protectants, anti-motility drugs and laxatives; 
 9 patients (45 per cent) were taking drugs which affected the respiritory system, e.g. 
bronchodilators, antihistamines and mucolytics; and, 
 6 patients (30 per  cent) were taking drugs which affected the endocrine system, e.g. anti-
diabetics, thyroid and anti-thyroid drugs and corticosteroids. 
According to the consensus panel, 19 patients (95 per cent) were taking at least one inappropriate 
medication that could be discontinued; the mean number of medications per patient that were 
considered inappropriate was 3 (range 0 to 7).   
The most commonly prescribed medication that was considered inappropriate were proton pump 
inhibiors (PPIs) in 11 patients (55 per cent); this medication was initiated in primary care by the 
patients’ General Practitioner (GP) prior to erlotinib use.  Other medication that was commonly 
prescribed in this patient group that was considered inappropriate were antiplatelets and lipid 
regulating drugs.  Among the patients taking antiplatelets, 5 were talking aspirin, while 1 was using 
clopidogrel; both agents were used for secondary prevention of cardiovascular events.  For patients 
taking lipid regulating agents, all 3 were taking HMG-CoA reductase inhibitors (“statins”) for either 
primary or secondary prevention of cardiovascular events.    
In contrast, the most common medication prescribed to this patient group that were considered 
appropriate were the corticosteroids and analgesics.  Indeed, among the patients taking a 
corticosteroid, 6 were taking dexamethasone; this was initiated in secondary care and was either 
used as an appeptite supplement or to treat oedema associated with cerebral metastases.  For 
patients using analgesics, 8 were taking NSAIDs, 9 opioids, and 10 non-opioids.    
 
Discussion 
Our results show that the majority of patients taking erlotinib with advanced lung cancer are using 
many inappropriate medications in view of their terminal prognosis.  The futile use of medication in 
patients with LLE has been previously reported in the literature for patients with cancer, advanced 
dementia and several studies have also specifically examined statin use in patients with LLE.  For 
example, Fede and colleagues assessed patients with advanced cancer and concluded among 87 
patients, 21 were taking at least one unnecessary medication8, while Stavrou and colleagues found 
that more than 30 per cent of patients who died of cancer were dispensed statins within 30 days of 
death.9 
Patients undergoing treatment for terminal lung cancer can be frightened, upset or angry so the 
issue of discontinuing inappropriate medications is not a priority. However, once the patient has 
come to terms with their prognosis, a discussion regarding their medications should be instigated.  
The timing of this discussion is difficult and should be a shared decision between the patient and the 
healthcare team with careful explanation of why it is necessary to discontinue inappropriate 
medications.  It is not clear who should instigate this discussion and recent work suggests that GPs 
would welcome training in shared care decision-making in relation to discontinuing inappropriate 
medication in elderly patients.10  Interestingly, the same study showed that GPs perceive stopping 
preventative medication as being more difficult when compared with medication used to treat 
symptomatic conditions as they believe patients may interpret a proposal to stop preventive 
medication as a sign of having been given up on.  Further work exploring the views of healthcare 
professionals regarding stopping inappropriate medication in a cancer context is warranted.   
A key finding of this work also showed that more than half of our patient population were taking 
erlotinib in combination with a proton pump inhibitor (PPI).  Given there is an established drug 
interaction between erlotinib and PPIs our results are of significant value.  Indeed, the absorption of 
erlotinib is pH dependant and increasing the pH of the stomach significantly reduces the absorption 
of erlotinib; for example, omeprazole decreased the erlotinib exposure [AUC] and maximum 
concentration [Cmax] by 46 % and 61 %, respectively.11. Recent works suggests that using PPIs in 
combination with erlotinib does not appear to significantly reduce the efficacy of erlotinib.16  
However, given that this interaction has not been studied in a large scale clinical population, it would 
be prudent to avoid the combination of erlotinib and PPIs; if acid suppression is necessary a H2 
receptor antagonist, such as ranitidine, should be used with a staggered dosing regimen.11     
There is the potential for pharmacists to become involved in the review of patients with terminal 
cancer to facilitate discontinuing inappropriate medication.  Indeed, Conlon and colleagues have 
recently described a pharmacist-led intervention around psychotropic prescribing, which utilized 
recommendations from the STOPP-START and Beers criteria to minimize inappropriate medication 
use.12  The STOPP-START13 and Beers criteria14 are both used for classifying appropriate and non-
appropriate medications in the elderly and have clear limitations in palliative care.15  However, these 
criteria used in combination with the framework developed by Holmes and colleagues7 may prove to 
be a useful starting point for clinical pharmacists offering this service to patients with LLE. 
While we believe these results are robust and have important implications for the treatment of lung 
cancer patients only patients from oncology units in the North of England were examined and the 
sample size was relatively small.  Generalisation of this work to all lung cancer patients in England 
and more widely should therefore be made carefully. 
Conclusion 
Patients taking erlotinib for the treatment of advanced or metastatic NSCLC take many inappropriate 
medications for the treatment or prevention of long-term conditions.  These patients should have 
their medications reviewed in the context of their original therapeutic goals. 
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Table 1. The type and frequency of medicine according to BNF classification  
BNF Classification 
 
Number of Medications 
 
Cardiovascular system 
Beta-adrenoceptor blocking drugs 
Drugs affecting RAS 
Anti-platelets 
Anticoagulants 
Diuretics 
Lipid regulating drugs 
Nitrates 
Calcium channel blockers 
Total 
 
 
 
2 
3 
6 
3 
3 
3 
1 
2 
23 
 
GI system 
Anti-secretory drugs 
Anti-diarrhoeals 
Laxatives 
Anti-spasmotics 
Total 
 
 
 
11 
1 
8 
1 
21 
 
Respiratory system 
Bronchodilators 
Corticosteroids 
Anti-histamines 
Mucolytics 
Cough preparations 
Total 
 
 
 
4 
4 
1 
2 
1 
12 
 
Endocrine system 
Anti-diabetics 
Thyroid and Anti-thyroid drugs 
Corticosteroids 
Drugs affecting bone metabolism 
Total 
 
 
 
1 
1 
6 
2 
10 
 
CNS system 
Hypnotics and Anxiolytics 
Psychoses and related disorders 
Antiemetics 
Antidepressants 
Analgesics (NSAIDs) 
 
 
6 
1 
2 
3 
8 
Analgesics (Opioids) 
Analgesics (Non-opioid) 
Antiepileptics 
Total  
 
9 
12 
5 
46 
 
Miscellaneous 
Vitamins, minerals and herbal supplements 
Total 
 
 
 
38 
38 
 
 
